Preoperative conversion therapy of camrelizumab combined with paclitaxel and nedaplatin for unresectable advanced esophageal squamous cell carcinoma: a phase 2 study.

BMC Med · 2025 · PMC12857139 · PMID 41456046

Europe PMC DOI

hedged sentences

0.0750

closest p · 1.5× alpha

0.0750

boldest claim

The sentences

showed a trendP = 0.075so close (0.05 < p ≤ 0.1)

Pathologically confirmed lymph node-positive (pN +) patients showed a trend toward lower OS ( P = 0.075) and had significantly worse DFS ( P < 0.05) compared to pN − patients (Fig. 5 C and D).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

(A, B) Responders with major pathological response (MPR) and pathological completer response (pCR) showed a trend toward improved OS compared to non-responders, though the difference did not reach statistical significance.

also in 111,027 other papers

highly significantno p-value reported

This comparable pCR rate is highly significant, as it was achieved in patients with a much higher tumor burden and more advanced disease at baseline, supporting the potency of the conversion regimen.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.